COMP <GO>
TCRT vs IMRN // REVENUE GROWTH (YOY)
Alaunos Therapeutics Inc. (NASDAQ) VS. Immuron Limited (NASDAQ) • 15-METRIC TALLY: TCRT 2
— IMRN 0
■ METRIC PARITY
LAST: $1.89 (-11.27%) • MKT CAP: $7.8M
revenue-growth
-50.00%
LAST: $0.92 (+2.48%) • MKT CAP: $7.4M
revenue-growth
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TCRT VS. IMRN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TCRT | IMRN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -50.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.0 | 32.0 | +18.00 | TCRT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.8M | $7.4M | $357.9K | TCRT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TCRT REV | IMRN REV | TCRT GROSS % | IMRN GROSS % | TCRT FCF | IMRN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.0K | — | — | — | -$3.0M | — |
| FY 2024 | $10.0K | — | — | — | -$5.0M | — |
| FY 2023 | $5.0K | — | — | — | -$30.1M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TCRT // BETA —
IMRN // BETA —